Target: CD195.
Clone: HEK/1/85a/7a.
Specificity: Clone HEK/1/85a/7a recognizes an epitope on human CCR5.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CCR5 is expressed on memory T cells, macrophages, and immature dendritic cells (DCs).
Background: CCR5 antibody, HEK/1/85a/7a, recognizes C-C chemokine receptor type 5 (CCR5), also known as CD195, CC-CKR-5, CHEMR13, and HIV-1 fusion coreceptor. CCR5 is a 45 kDa seven-transmembrane G-protein-coupled receptor (GPCR). CCR5 is expressed on a subset of memory T cells, macrophages, and immature dendritic cells (DCs) and is upregulated by proinflammatory cytokines. CCR5 binds to inflammatory CC-chemokines, including CCL3 (macrophage inflammatory protein (MIP)-1α), CCL4 (MIP-1β), and RANTES, which increases intracellular calcium levels and results in cytoskeletal rearrangement and chemotactic cell migration. CCR5 is also the coreceptor for HIV-1 following binding of viral gp120 to CD44-7. The levels of CCR5 on cells influence the rate of entry of HIV-1, and patients with lower levels of CCR5 exhibit immunity against infection. CCR5 also contributes to other human diseases, including type I diabetes and cancer.
Immunogen: CHO cells transfected with full-length human CD195 (CCR5).
Concentration: ≥ 5.0 mg/ml.
Formulation: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
